TY - JOUR
T1 - Low rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program
AU - Felsen, Uriel R.
AU - Fishbein, Dawn A.
AU - Litwin, Alain H.
N1 - Funding Information:
For D. A. Fishbein, this project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the National Institute of Allergy and Infectious Disease. For D. A. Fishbein, this manuscript research was previously funded by NIDA K23 DA18623.
PY - 2010/10
Y1 - 2010/10
N2 - Patients with chronic hepatitis C virus (HCV) are at increased risk for complications of liver disease if they become infected with the hepatitis A (HAV) or hepatitis B (HBV) viruses. The authors examined the rates of testing for HAV, HBV, and HCV, as well as rates of vaccination against HAV and HBV in patients with chronic HCV in a random sample (N = 207) of medical records of patients enrolled in a methadone maintenance program. Almost all patients reviewed were tested for HAV, HBV, and HCV. Of the 111 patients with chronic HCV, 53 (48.6%) and 68 (63%) lacked immunity to HAV and HBV, respectively. Of those lacking immunity, 29 (54.7%) and 2 (2.9%) were vaccinated for HAV and HBV, respectively. Despite high rates of testing for HAV, HBV, and HCV at a methadone maintenance program, approximately half of those with chronic HCV eligible for the HAV vaccine received it, and few of those eligible for HBV vaccine received it.
AB - Patients with chronic hepatitis C virus (HCV) are at increased risk for complications of liver disease if they become infected with the hepatitis A (HAV) or hepatitis B (HBV) viruses. The authors examined the rates of testing for HAV, HBV, and HCV, as well as rates of vaccination against HAV and HBV in patients with chronic HCV in a random sample (N = 207) of medical records of patients enrolled in a methadone maintenance program. Almost all patients reviewed were tested for HAV, HBV, and HCV. Of the 111 patients with chronic HCV, 53 (48.6%) and 68 (63%) lacked immunity to HAV and HBV, respectively. Of those lacking immunity, 29 (54.7%) and 2 (2.9%) were vaccinated for HAV and HBV, respectively. Despite high rates of testing for HAV, HBV, and HCV at a methadone maintenance program, approximately half of those with chronic HCV eligible for the HAV vaccine received it, and few of those eligible for HBV vaccine received it.
KW - Hepatitis
KW - methadone
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=77957915049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957915049&partnerID=8YFLogxK
U2 - 10.1080/10550887.2010.509281
DO - 10.1080/10550887.2010.509281
M3 - Article
C2 - 20924882
AN - SCOPUS:77957915049
SN - 1055-0887
VL - 29
SP - 461
EP - 465
JO - Journal of Addictive Diseases
JF - Journal of Addictive Diseases
IS - 4
ER -
